Lexeo Therapeutics, Inc. (LXEO), a clinical-stage genetic medicine company pioneering novel treatments for cardiovascular diseases, has finalized the pivotal study design for gene therapy candidate LX2006 in Friedreich Ataxia.
The study, dubbed SUNRISE-FA 2, is an open-label pivotal study in which 13 participants aged 16 years and older will receive a single intravenous administration of high-dose LX2006 compared with 13 participants untreated with LX2006 (untreated control). The study does not include a placebo or sham procedure for participants in the untreated control arm.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Prabha Kurup
For comments and feedback: contact editorial@rttnews.com